DIVISLAB - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.8
| Stock Code | DIVISLAB | Market Cap | 1,62,973 Cr. | Current Price | 6,137 ₹ | High / Low | 7,078 ₹ |
| Stock P/E | 63.3 | Book Value | 578 ₹ | Dividend Yield | 0.49 % | ROCE | 20.6 % |
| ROE | 15.6 % | Face Value | 2.00 ₹ | DMA 50 | 6,264 ₹ | DMA 200 | 6,235 ₹ |
| Chg in FII Hold | 0.69 % | Chg in DII Hold | -0.50 % | PAT Qtr | 653 Cr. | PAT Prev Qtr | 696 Cr. |
| RSI | 43.3 | MACD | -28.2 | Volume | 1,81,338 | Avg Vol 1Wk | 2,03,743 |
| Low price | 4,942 ₹ | High price | 7,078 ₹ | PEG Ratio | -6.88 | Debt to equity | 0.01 |
| 52w Index | 56.0 % | Qtr Profit Var | 9.88 % | EPS | 94.8 ₹ | Industry PE | 27.6 |
📊 Chart & Trend Analysis: DIVISLAB is trading at ₹6,137, slightly below its 50 DMA (₹6,264) and 200 DMA (₹6,235), indicating mild weakness. RSI at 43.3 suggests the stock is approaching oversold territory. MACD at -28.2 confirms bearish undertone. Bollinger Bands show price leaning towards the lower band, with support near ₹5,950–6,000 and resistance around ₹6,264–6,300.
📈 Momentum Signals: Current volume (1.81 lakh) is lower than the 1-week average (2.03 lakh), showing reduced participation. RSI below 50 and negative MACD reinforce bearish bias, though oversold conditions may trigger a short-term bounce.
💡 Entry Zone: Optimal entry around ₹5,950–6,100 (near support).
🚪 Exit Zone: Resistance seen at ₹6,264 (50 DMA) and ₹6,300–6,350. Profit booking advised near these levels.
🔎 Trend Status: The stock is currently consolidating with bearish bias. A breakout above ₹6,264 would indicate recovery momentum.
Positive
- Strong ROCE (20.6%) and ROE (15.6%) reflect efficient capital use.
- Debt-free balance sheet (Debt-to-equity 0.01) ensures financial stability.
- EPS of ₹94.8 supports earnings visibility.
- FII holding increased (+0.69%), showing foreign investor confidence.
Limitation
- High P/E (63.3) compared to industry average (27.6) suggests overvaluation.
- Trading below both 50 DMA and 200 DMA highlights weak technical strength.
- PEG ratio (-6.88) indicates poor growth-to-valuation alignment.
- Volume participation is lower than average, showing reduced market interest.
Company Negative News
- Sequential PAT decline (₹653 Cr vs ₹696 Cr) indicates margin pressure.
- DII holding decreased (-0.50%), showing reduced domestic institutional support.
Company Positive News
- Quarterly profit variation (+9.88% YoY) highlights resilience despite sequential decline.
- FII holding increased (+0.69%), reflecting foreign investor confidence.
Industry
- Industry P/E at 27.6 is much lower than DIVISLAB’s P/E, suggesting peers are more attractively valued.
- Pharmaceutical sector remains strong, supported by global demand for APIs and specialty formulations.
Conclusion
⚖️ DIVISLAB shows strong fundamentals (debt-free, healthy ROE/ROCE, foreign investor support) but faces valuation concerns and weak technical momentum. Short-term consolidation with bearish bias is evident. Entry near ₹5,950–6,100 offers margin of safety, while exits should be considered near ₹6,264–6,350. Long-term investors may hold for sector resilience, but traders should wait for confirmation above 50 DMA before aggressive buying.
Would you like me to extend this into a peer benchmarking overlay (e.g., comparing DIVISLAB with Sun Pharma, Dr. Reddy’s, and Cipla) to highlight relative strength and sector rotation opportunities?